申请人:CS Pharmasciences, Inc.
公开号:US20160214996A1
公开(公告)日:2016-07-28
The compounds and salts of the present invention inhibit kinases, especially the anaplastic lymphoma kinase (ALK) and the HGF receptor tyrosine kinase (RTK) c-Met, and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.